Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients
with NSCLC and have led to unprecedented improvements in response rates and survival …

The recent development of immune checkpoint inhibitors (ICIs) has led to promising advances
in the treatment of patients with NSCLC and SCLC with advanced or metastatic disease. …

The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC)
targetable by small-molecule inhibitors, and the development of immunotherapies, have …

We have sequenced the genomes of 110 small cell lung cancers (SCLC), one of the deadliest
human cancers. In nearly all the tumours analysed we found bi-allelic inactivation of TP53 …

Polarization of tumor-associated macrophages (TAMs) to a proangiogenic/immune-suppressive
(M2-like) phenotype and abnormal, hypoperfused vessels are hallmarks of malignancy, …

Tissue gene expression profiling is performed on homogenates or on populations of
isolated single cells to resolve molecular states of different cell types. In both approaches, …

… Borczuk MD e , Johan Botling MD f , Lukas Bubendorf MD g , Lucian Chirieac MD h , Gang
Chen MD i , Teh-Ying Chou MD, PhD j , Jin-Haeng Chung MD, PhD k , Sanja Dacic MD, PhD …

Recent studies on the immunoglobulin variable heavy chain (IgV H ) genes have revealed
that B-cell chronic lymphocytic leukemia (B-CLL) consists of at least 2 clinical entities with …

Introduction A grading system for pulmonary adenocarcinoma has not been established. The
International Association for the Study of Lung Cancer pathology panel evaluated a set of …

Improved methods are needed for in situ characterization of post-translational modifications
in cell lines and tissues. For example, it is desirable to monitor the phosphorylation status of …